AstraZeneca and Eli Lilly continue trial of AZD3293 for Alzheimer's after safety analysis

8 April 2016

Anglo-Swedish AstraZeneca (LSE: AZN) and the USA's Eli Lilly (NYSE: LLY) have announced that their study of AZD3293 as a potential treatment for early Alzheimer’s disease, will continue into Phase III.

The two pharma majors announced an alliance in 2014 for the development and commercialization of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor, and this new milestone means Eli Lilly will pay AstraZeneca $100 million under the terms of the agreement.

AMARANTH, the Phase II/III study of AZD3293, has been investigating its safety and efficacy and testing the hypothesis that it is a disease-modifying treatment for patients with early Alzheimer’s disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK